More from the Pipeline of Clinical Research on SELECTED SYSTEMIC THERAPIES FOR ATOPIC DERMATITIS.
Year: 2019
Type: article
Abstract: Many systemic therapies are under development for atopic dermatitis, many of which are injectable monoclonal antibodies that inhibit specific pathways involved in the pathogenesis of the disease. Most are currently under development, however, there are preliminary studies with subcutaneous omalizumab (IgE-directed therapy), and oral apremilast (phosphodiesterase-4 [PDE-4] inhibition. Further studies are needed with these agents. This article discusses various agents that address several potential therapeutic approaches, including IgE-directed therapy, anti-IL-31, anti-IL-5, anti-IL-22, PDE-4 inhibition, and thymic stromal lymphopoietin (TSLP)-directed therapy.
Source: Europe PMC (PubMed Central)
Author: James Q Del Rosso
Institution: Touro University Nevada
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2963262370